Medicines Development for Global Health’s (MDGH) Moxidectin Receives FDA Approval for Onchocerciasis (River Blindness)

 Medicines Development for Global Health’s (MDGH) Moxidectin Receives FDA Approval for Onchocerciasis (River Blindness)

Medicines Development for Global Health’s (MDGH) Moxidectin Receives FDA Approval for Onchocerciasis (River Blindness)

Shots:

  • The approval is based on two clinical studies results assessing Moxidectin vs SoC Ivermectin in patients with river blindness aged ≥ 12 yrs.
  • The study resulted in meeting 1EPswith superiority of Moxidectin vs SoC Ivermectin and resulted in suppression of microfilariae in the skin
  • Moxidectin (8mg, PO) is macrocyclic lactone anthelmintic medication active against O.volvulus microfilariae and has also received FDA’s PRV on 13 Jun, 2018 with its accelerated NDA review from 10 to 6mos.

Click here to read full press release/ article | Ref: Medicines Development for Global Health | Image: CmocroI

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post